Boston Scientific Corporation $BSX Shares Sold by APG Asset Management N.V.

Key Points

• APG Asset Management N.V. reduced its stake in Boston Scientific Corporation by 4.5%, selling 45,951 shares and holding 975,266 shares valued at approximately $91 million.
• Insider transactions included the sale of 17,313 shares by EVP Arthur C. Butcher and 164,443 shares by CEO Michael F. Mahoney, indicating a significant decrease in their holdings.
• Boston Scientific reported a revenue of $5.06 billion for the previous quarter, surpassing expectations, and set projected earnings for Q3 2025 between $0.700-0.720 EPS.

APG Asset Management N.V. reduced its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 4.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 975,266 shares of the medical equipment provider's stock after selling 45,951 shares during the period. APG Asset Management N.V. owned 0.07% of Boston Scientific worth $91,080,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC lifted its holdings in Boston Scientific by 6.2% in the first quarter. Smartleaf Asset Management LLC now owns 19,895 shares of the medical equipment provider's stock valued at $1,977,000 after acquiring an additional 1,162 shares during the last quarter. Bahl & Gaynor Inc. lifted its holdings in Boston Scientific by 68.7% in the first quarter. Bahl & Gaynor Inc. now owns 4,064 shares of the medical equipment provider's stock valued at $410,000 after acquiring an additional 1,655 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in Boston Scientific by 4.3% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 749,398 shares of the medical equipment provider's stock valued at $75,599,000 after acquiring an additional 31,179 shares during the last quarter. Haverford Trust Co acquired a new position in Boston Scientific in the first quarter valued at approximately $201,000. Finally, Groupe la Francaise lifted its holdings in Boston Scientific by 13.1% in the first quarter. Groupe la Francaise now owns 335,082 shares of the medical equipment provider's stock valued at $33,591,000 after acquiring an additional 38,701 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Down 0.4%

Shares of Boston Scientific stock traded down $0.45 during trading hours on Wednesday, reaching $105.94. 5,706,436 shares of the company were exchanged, compared to its average volume of 7,524,457. Boston Scientific Corporation has a 1 year low of $79.03 and a 1 year high of $108.94. The stock's fifty day moving average is $104.27 and its 200 day moving average is $102.15. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The firm has a market cap of $156.98 billion, a PE ratio of 63.06, a PEG ratio of 2.53 and a beta of 0.66.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the prior year, the company earned $0.62 earnings per share. The company's revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on BSX. Raymond James Financial upped their price objective on Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a report on Thursday, July 24th. Truist Financial upped their price objective on Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a report on Thursday, July 24th. Oppenheimer boosted their target price on Boston Scientific from $110.00 to $118.00 and gave the company a "market perform" rating in a research report on Thursday, July 24th. Barclays boosted their target price on Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. Finally, Erste Group Bank raised Boston Scientific to a "strong-buy" rating in a research report on Thursday, May 8th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $117.50.

Insider Buying and Selling at Boston Scientific

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the company's stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the sale, the director owned 2,081 shares of the company's stock, valued at approximately $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares of the company's stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 345,029 shares of company stock valued at $35,976,603. Insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.